Phase I/IIa Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumor Malignancies
Latest Information Update: 10 Jun 2020
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Cerulean Pharma; NewLink Genetics Corporation
- 21 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History